Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.01 HKD | +2.39% | -4.96% | -25.78% |
06-07 | Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023 | CI |
05-13 | Tong Ren Tang Chinese Medicine Appoints CEO | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 11.63 for the current year and 8.98 for next year, earnings multiples are highly attractive compared with competitors.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.78% | 943M | - | ||
+54.61% | 815B | C+ | ||
+44.25% | 654B | B | ||
-6.33% | 354B | C+ | ||
+20.62% | 337B | B- | ||
+10.44% | 302B | C+ | ||
+18.45% | 247B | B+ | ||
+2.09% | 229B | A+ | ||
+13.03% | 219B | B- | ||
+8.61% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3613 Stock
- Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited